Patents Examined by Li Ni Komatsu
-
Patent number: 9919028Abstract: Disclosed herein are autoclavable formulations of cyclosporin A Form 2, methods of making such formulations, and methods of treating diseases of the eye with such formulations.Type: GrantFiled: June 2, 2016Date of Patent: March 20, 2018Assignee: Allergan, Inc.Inventors: Wendy M. Blanda, Hongwen Ma Rivers, David A. Marsh, Michelle Luu
-
Patent number: 9907835Abstract: The present invention provides a novel albumin-free preparation of Factor VIII has a high amount of salt and a low concentration of sugar and of glycine. The high salt provides stability and an elegant cake structure as the major crystalline component. The sugar and glycine provide a complex amorphous matrix together with some amorphous non-crystallized salt for stabilization of Factor VIII. This formulation is suitable for B-domain deleted Factor VIII that requires a high ionic strength environment for stability. The addition of low amount of glycine to the sucrose prevents the crystallization of salt. This results in an amorphous matrix comprising of glycine, sucrose, and salt. This amorphous matrix provides a stabilizing environment where Factor VIII is protected by three stabilizers; amino acid (glycine), sugar (sucrose or trehalose), and salt (NaCl). Such an amorphous matrix that can stabilize the Factor VIII across lyophilization and during storage as a lyophile.Type: GrantFiled: March 30, 2015Date of Patent: March 6, 2018Assignee: Advanced Bioscience Farmacêutica LTDAInventor: Rajiv Nayar
-
Patent number: 9901615Abstract: The preset invention relates to a new method or composition for treating a gastric ulcer, preventing or treating an infection of H. pylori, particularly multidrug resistant H. pylori, using an antimicrobial peptide, a functional derivate, fragment or variant thereof, wherein the antimicrobial peptide is selected from the group consisting of Epi-1, TPs and combination thereof.Type: GrantFiled: April 14, 2016Date of Patent: February 27, 2018Assignees: ACADEMIA SINICA, NATIONAL TAIWAN OCEAN UNIVERSITYInventors: Jyh-Yih Chen, Chang-Jer Wu
-
Patent number: 9901621Abstract: The present invention relates to a composition for preventing or treating hyperlipidemia, fatty liver disease or arteriosclerosis, comprising an oxyntomodulin derivative as an active ingredient. The oxyntomodulin derivative has a high ability to activate GLP-1 receptor and glucagon receptor compared to native oxyntomodulin and has the effects of reducing the blood total cholesterol, low-density cholesterol and triglyceride levels that were increased by high-fat diet, and increasing high-density cholesterol levels and the high-density cholesterol/low-density cholesterol ratio. Thus, the oxyntomodulin derivative can be effectively used for the treatment of hyperlipidemia and related diseases.Type: GrantFiled: March 31, 2016Date of Patent: February 27, 2018Assignee: Hanmi Pharm. Co., Ltd.Inventors: Sung Youb Jung, Jin-Sun Kim, Myung Hyun Jang, Sang Hyun Lee, In Young Choi, Se Chang Kwon
-
Patent number: 9901618Abstract: Peptide system including at least one peptide blocking the presynaptic release of glutamate. The peptide has the sequence SEQ ID NO 5: GRKKRRQRRRPPIEQSIEQEEGLNRS and/or sequence SEQ ID NO 8: GRKKRRQRRRPPMSEYNATQSDYRER for use in treating pathologies associated with glutamate excitotoxicity.Type: GrantFiled: March 6, 2015Date of Patent: February 27, 2018Inventors: Marco Feligioni, Robert Giovanni Nistico′
-
Patent number: 9884125Abstract: Insulin conjugates comprising an insulin molecule covalently attached to at least one bi-dentate linker having two arms, each arm independently attached to a ligand comprising a saccharide and wherein at least one ligand of the linker is fucose are disclosed. The insulin conjugates display a pharmacokinetic (PK) and/or pharmacodynamic (PD) profile that is responsive to the systemic concentrations of a saccharide such as glucose or alpha-methylmannose even when administered to a subject in need thereof in the absence of an exogenous multivalent saccharide-binding molecule such as Con A.Type: GrantFiled: October 2, 2014Date of Patent: February 6, 2018Assignee: MERCK SHARP & DOHME CORP.Inventors: Songnian Lin, Christopher R. Moyes
-
Patent number: 9879052Abstract: A series of integrin blockers that present strong angiogenesis inhibiting performance, high integrin affinity and integrin-bonding capacity is provided. This series of integrin blockers can be adopted in treatment of solid tumors and rheumatoid arthritis. Specifically, said series of integrin blockers include polypeptide I, polypeptide II and polypeptide III (see SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3) that can be adopted in treatment of solid tumors and rheumatoid arthritis. This invention also relates to application of these three integrin-blocking polypeptides in preparation of anti-tumor drugs, wherein the tumors that can be treated include those primary or secondary cancers originated from head and neck region or other organs such as brain, thyroid, esophagus, pancreas, lung, liver, stomach, breast, kidney, gallbladder, colon, rectum, ovary, cervix, uterus, prostate, bladder and testicle, as well as melanoma and sarcomas.Type: GrantFiled: August 24, 2016Date of Patent: January 30, 2018Inventor: Hanmei Xu
-
Patent number: 9872889Abstract: The present disclosure describes methods of treating angiogenic disorders of the eye, such as macular degeneration, restenosis following glaucoma treatment or diabetic retinopathy, by administering an activator of C-X-C chemokine receptor 3 (CXCR3). In some embodiments, the activator of CXCR3 is interferon-?-inducible 10 kDa protein (IP-10) or a fragment or variant thereof, such as a fragment comprising or consisting of the C-terminal ?-helix of IP-10. In other embodiments, the activator of CXCR3 is platelet factor 4 (PF4) or a fragment or variant thereof.Type: GrantFiled: August 24, 2016Date of Patent: January 23, 2018Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Alan H. Wells, Cecelia C. Yates-Binder, Joel S. Schuman
-
Patent number: 9862748Abstract: Peptide compounds based on the CAP37 (cationic antimicrobial protein of Mr 37 kDa) protein are disclosed, along with methods for treating various infections, wounds, and conditions, and methods of promoting healing and acceptance of grafts, using compositions containing these peptides.Type: GrantFiled: June 30, 2015Date of Patent: January 9, 2018Assignee: The Board of Regents of the University of OklahomaInventor: Heloise Anne Pereira
-
Patent number: 9862746Abstract: The present invention relates to MLL fusion proteins (e.g., AF9 and ENL), which activate target genes in part via recruitment of histone methyltransferase DOT1L. In particular, the present invention provides the AF9/ENL binding site in DOT1L and agents that block the protein-protein interactions between AF9/ENL and DOT1L, therefore inhibiting the activity of DOT1L, and inhibiting MLL-fusion protein associated leukemia.Type: GrantFiled: February 14, 2014Date of Patent: January 9, 2018Assignee: The Regents of the University of MichiganInventors: Zaneta Nikolovska-Coleska, Chenxi Shen, Jay Hess
-
Patent number: 9855319Abstract: The present invention provides a novel albumin-free formulation of recombinant Factor VIII that does not require calcium ions as an added formulation excipient. The absence of calcium chloride in the formulation results in a number of improvements and benefits for a Factor VIII formulation. This invention allows a Factor VIII formulation that can be lyophilized more efficiently as the absence of calcium ions will increase primary glass transition of the amorphous phase. The absence of free calcium ions in the formulation will also improve the stability of the formulation as metal-dependent oxidation reactions will be avoided and the protein molecule will not be subjected to chemical instabilities. Finally, the absence of calcium will further simplify the Factor VIII formulation by reducing the number of excipients in the formulation.Type: GrantFiled: March 30, 2015Date of Patent: January 2, 2018Assignee: ADVANTECH BIOSCIENCE FARMACÊUTICA LTDAInventor: Rajiv Nayar
-
Patent number: 9856290Abstract: The present disclosure provides glycosylated oligopeptides having the sequence Palmitoyl-X1-Lys-X2-X3-Lys-X4-OH, where: X1 is: absent, Ser having a glycosylated side chain, or Asn having a glycosylated side chain; X2 is: Thr, Thr having a glycosylated side chain, Asn having a glycosylated side chain, or Ser having a glycosylated side chain; X3 is: Thr, or Thr having a glycosylated side chain; X4 is: Ser, or Ser having a glycosylated side chain. At least one of X1, X2, X3 and X4 is an amino acid having a glycosylated side chain. Each glycosylated side chain is, independently, glycosylated with a carbohydrate selected from the group consisting of: glucose, N-acetyl-glucosamine, galactose, N-acetyl-galactosamine, mannose, maltose, lactose, rhamnose, cellobiose, xylose, and fucose. Each hydroxyl group on the carbohydrate is, independently, OH or acetylated.Type: GrantFiled: December 9, 2014Date of Patent: January 2, 2018Assignee: Sussex Research Laboratories Inc.Inventors: Kenneth Brady Clark, Remmick So, Vanja Vukic
-
Patent number: 9856300Abstract: Disclosed are compositions and methods for modulating Dpy-30 binding activity. The compositions may include peptides or peptidomimetics thereof that are related to radial spoke protein 3 (RSP3) or absent, small, homeotic discs 2-like protein (Ash2L) and that bind to Dumpy-30 protein (Dpy-30).Type: GrantFiled: June 17, 2016Date of Patent: January 2, 2018Assignee: Marquette UniversityInventors: Pinfen Yang, Priyanka Sivadas
-
Patent number: 9854821Abstract: The present invention relates to a process for producing a casein protein product comprising the steps of: —providing a casein concentrate starting material, —heat-treating the material, —cooling the heat-treated material, —subjecting the cooled material to a treatment with a crosslinking enzyme, —optionally subjecting the cooled material to a treatment with a coagulant and —processing the material into the casein protein product/allowing the casein protein product to form.Type: GrantFiled: June 26, 2013Date of Patent: January 2, 2018Assignee: VALIO LTD.Inventor: Päivi Myllärinen
-
Patent number: 9849158Abstract: The present invention relates to binding proteins specific for VEGF-A, in particular to recombinant binding proteins comprising a polyethylene glycol moiety and a binding domain, which inhibits VEGF-Axxx binding to VEGFR-2. Examples of such recombinant binding proteins are proteins which comprise an ankyrin repeat domain with the desired binding specificity, and a polyethylene glycol moiety. The binding proteins are useful in the treatment of cancer and other pathological conditions, e.g. eye diseases such as age-related macular degeneration.Type: GrantFiled: February 4, 2016Date of Patent: December 26, 2017Assignee: Molecular Partners AGInventors: Hans Kaspar Binz, Patrik Forrer, Michael Tobias Stumpp
-
Patent number: 9834589Abstract: The invention provides a polypeptide that specifically binds to CTLA-4, particularly human CTLA-4.Type: GrantFiled: June 25, 2014Date of Patent: December 5, 2017Assignee: ALLIGATOR BIOSCIENCE ABInventors: Peter Ellmark, Christina Furebring, Eva Dahlen
-
Patent number: 9821086Abstract: Hydrogels comprising a macromolecular matrix and water may be used for aesthetic fillers, for example, dermal fillers. The macromolecular matrix may include a crosslinked combination of hyaluronic acid and collagen.Type: GrantFiled: December 8, 2015Date of Patent: November 21, 2017Assignee: Allergan, Inc.Inventors: Xiaojie Yu, Nicholas J. Manesis, Jacob Pollock
-
Patent number: 9821037Abstract: A compound is provided which comprises at least a portion of an amino acid linker-domain from squalene synthase. In alternative forms, the compound can include the amino-acid linker-domain from various fungus, including S. cerevisiae or the compound can be the functional equivalent and/or mimics an amino acid linker-domain from squalene synthase. A pharmaceutical composition includes the compound and may further include a pharmaceutical carrier. A method is provided for treating or controlling cholesterol metabolism and ergosterol metabolism in non-fungal organisms. One method includes a therapeutic treatment in humans by administering a therapeutically effective amount of the compound or pharmaceutical composition, to a patient in need of treatment, therefrom.Type: GrantFiled: April 21, 2014Date of Patent: November 21, 2017Assignee: University of Kentucky Research FoundationInventors: Joe Chappell, Tom D. Niehaus, Kristin Linscott
-
Patent number: 9809626Abstract: The invention provides compounds of formula (I): and salts thereof, wherein X and Y have any of the values defined herein. The compounds inhibit bacterial RNA polymerase, inhibit bacterial growth, and have applications in, analysis of RNA polymerase structure and function, control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, antibacterial therapy, and drug discovery.Type: GrantFiled: February 17, 2017Date of Patent: November 7, 2017Assignee: Rutgers, the State University of New JerseyInventors: Richard H. Ebright, Yon W. Ebright, Yu Feng, David Degen
-
Patent number: 9809632Abstract: Disclosed herein are chimeric proteins that include one or more double stranded nucleic acid binding domains (dsNABD) and one or more polyHis domains, and compositions that further include a therapeutic double stranded nucleic acid and a targeting ligand bound to the therapeutic double stranded nucleic acid, wherein the dsNABD of the chimeric protein is bound to the therapeutic double stranded nucleic acid, and uses of the compositions to treat disease.Type: GrantFiled: October 22, 2014Date of Patent: November 7, 2017Assignee: University of Washington Through its Center for CommercializationInventors: Xiaohu Gao, Hong Yan Liu